August 5, 2024- Luxor Scientific, a leader in clinical diagnostics, has entered into a strategic partnership with Capstone Health Alliance. This collaboration will grant Capstone’s membership of health systems, independent hospitals, and physician offices across the country access to cutting-edge diagnostic testing and expedited results.
A full-service, privately held medical and research laboratory, Luxor Scientific offers innovative testing solutions that often lead the industry in response to healthcare concerns nationwide. Driven by a team of industry leading scientists and operational leaders, Luxor has developed proprietary technology to increase speed and provide accurate results.
• OWLiver®, the only serum test based off the MASEF Score® able to identify all damaging phases of MASLD, formally known as NAFLD.
• Epidermal Nerve Fiber Density (ENFD) Testing, a highly sensitive and specific test done in-office for documenting small fiber peripheral neuropathy.
• Clinical Medication Monitoring & Toxicology, extensive testing of urine and oral fluid samples for over 100 drugs including emerging novel illicits xylazine, pentylone, nitazenes, bromazolam, and tianeptine.
• CannabisConfirm™, a custom solution for identifying if patients have taken Delta-8- or Delta-9-THC amidst the significant increase in usage of CBD products.
• Molecular Pathogen, both traditional microbiology and rapid PCR testing for infectious diseases.